J The management of chronic heart failure. N Engl J Med.
1996;335490- 498Link to Article
SCollaborative Group on ACE Inhibitor Trials, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA.
1995;2731450- 1456Link to Article
J-P Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation.
1998;981184- 1191Link to Article
DE An epidemic of heart failure? recent evidence from Europe. Eur Heart J. 1998;19
JG Heart failure: a medical hydra. Lancet.
SI1- SI2Link to Article
N Translation of clinical trial results into practice. Eur Heart J. 1998;19
W Clinical aspects of heart failure: high output heart failure: pulmonary edema. Braunwald
Eed.Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa WB Saunders Co1997;445- 456
JN Consensus recommendations for the management of chronic heart failure. Am J Cardiol.
1999;831A- 38ALink to Article
et al. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril and Survival Study (ATLAS) [abstract]. Eur Heart J. 1998;19
W Pathophysiology of congestive heart failure. Clin Cardiol.
1992;155- 12Link to Article
et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med.
1998;3391810- 1816Link to Article
W Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol.
1993;2249A- 55ALink to Article
Criteria Committee NYHA Inc, Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. Boston, Mass Little Brown & Co Inc1964;114
A Comparative reproducibility and validity of symptoms for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation.
1981;641227- 1234Link to Article
et al. Effect of encouragement on walking test performance. Thorax.
1984;39818- 822Link to Article
MBDuke University Clinical Cardiology Studies (DUCCS) Exercise Group, Improvement in the mechanical efficiency of walking: an explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. Am Heart J.
1998;135107- 114Link to Article
D The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol.
1993;226A- 13ALink to Article
B Exercise tolerance in congestive heart failure: role of cardiac function, peripheral blood flow and muscle metabolism and effect of treatment. Am J Med.
1988;8475- 82Link to Article
MR Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13
et al. ATLAS Study Group, Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation.
1999;1002312- 2318Link to Article
Editorial Advisory Board, Heart failure: impact and evolving concepts. Curr Issues Heart Fail. 1999;11- 7
J Where are all the women with heart failure? J Am Coll Cardiol.
1997;301417- 1419Link to Article
NB Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J.
1997;133703- 710Link to Article
American Heart Association, 1998 Heart and Stroke Statistical Update. Dallas, Tex American Heart Association1997;
M How should physicians view heart failure? the philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol.
1993;713C- 11CLink to Article
RW Sympathetic activation in heart failure and its treatment with β-blockade. Arch Intern Med.
1999;159225- 234Link to Article
M The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol.
1992;20248- 254Link to Article
E Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation.
1990;811161- 1172Link to Article
J Structural basis for heart failure: ventricular remodeling and its pharmacologic inhibition. Circulation.
1995;912504- 2507Link to Article
E Pathophysiology of heart failure. Braunwald
Eed.Braunwald Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa WB Saunders Co1997;394- 420
E Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med.
1988;31980- 86Link to Article
et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation.
1994;892852- 2859Link to Article
et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation.
1997;961976- 1982Link to Article
MR Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation.
1996;942285- 2296Link to Article
et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J.
1997;18254- 258Link to Article
G IV Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation.
1992;85790- 804Link to Article
KT Cardiac myocyte necrosis induced by angiotensin II. Circ Res.
1991;691185- 1195Link to Article
VG Apoptosis in heart failure. Prog Cardiovasc Dis.
1998;40549- 562Link to Article
TL Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis.
1998;4117- 24Link to Article
M Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol. 1998;275H626- H631
D The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines. J Card Fail.
S165- S172Link to Article
et al. Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest. 1995;73771- 787
CS Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol. 1998;275H250- H258
M Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med.
1990;323236- 241Link to Article
G Congestive heart failure. Stein
Jed.Internal Medicine. 5th ed. St Louis, Mo Mosby–Year Book Inc1998;156- 175
B Ischemic and nonischemic heart failure do not require different treatment strategies. J Cardiovasc Pharmacol. 1999;33
SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA.
1991;2653255- 3264Link to Article
et al. SHEP Cooperative Research Group, Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA.
1997;278212- 216Link to Article
K The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail.
1997;3249- 254Link to Article
BRTorsemide Investigators Group, Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994;14514- 521
CS Pirotanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther.
1986;40587- 594Link to Article
S Effect of diuresis on the performance of the failing left ventricle in man. Am J Med.
1981;70234- 239Link to Article
et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment [abstract]? Circulation. 1995;92I- 395
J Sodium and water balance in chronic congestive heart failure. J Clin Invest.
1986;771441- 1452Link to Article
AM Effect of digitalization on urinary excretion of water, sodium, potassium and chloride in heart failure. J Egypt Med Assoc. 1968;51638- 644
AD Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation.
1992;86439- 445Link to Article
Captopril Multicenter Research Group, A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol.
1983;2755- 763Link to Article
JNThe V-HeFT VA Cooperative Studies Group, Functional capacity in heart failure. Comparison of methods for assessment and their relation to other indexes of heart failure. Circulation. 1993;87
The SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med.
1991;325293- 302Link to Article
et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med.
1991;325303- 310Link to Article
The CONSENSUS Trial Study Group, The effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med.
1987;3161429- 1435Link to Article
BM Differences between primary care physicians and cardiologists in the management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol.
1997;30518- 526Link to Article
JR Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J.
1994;71584- 587Link to Article
J Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J.
1998;19L15- L21Link to Article
M Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol.
1996;281323- 1327Link to Article
PA The Network Study: the effect of dose of ACE-inhibitor on outcome in patients with heart failure [abstract]. J Am Coll Cardiol.
1996;27141ALink to Article
N Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart.
1996;75576- 581Link to Article
K Current and novel pharmacologic approaches in advanced heart failure. Am Heart J.
S249- S263Link to Article
et al. SAVE Investigators, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med.
1992;327669- 677Link to Article
The Acute Infarction Rampiril Efficacy (AIRE) Study, Effect of rampiril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342821- 828
et al. Trandolapril Cardiac Evaluation (TRACE) Study Group, A clinical trial of the angiotensin-converting–enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med.
1995;3331670- 1676Link to Article
The SOLVD Investigators, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med.
1992;327685- 691Link to Article
MJ Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol.
1999;33916- 923Link to Article
I Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J.
1975;371022- 1036Link to Article
The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, 3-Year follow-up of patients randomized in the Metoprolol in Dilated Cardiomyopathy Trial. Lancet. 1998;3511180- 1181
The Australia and New Zealand Heart Failure Research Collaborative Group, Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet.
1997;349375- 380Link to Article
CIBIS Investigators and Committees, A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation.
1994;901765- 1773Link to Article
et al. US Carvedilol Heart Failure Study Group, Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation.
1996;942800- 2806Link to Article
et al. RESOLVD Study Group, Effects of metoprolol-CR in patients with ischaemic and dilated cardiomyopathy: the RESOLVD pilot study (phase II) [abstract]. Eur Heart J.
1998;19308Link to Article
The International Steering Committee, Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol.
1997;8054J- 58JLink to Article
S Clinical studies on beta blockers and heart failure preceding the MERIT-HF Trial. Am J Cardiol.
1997;8050J- 53JLink to Article
CIBIS II Steering Committee, Design of the Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Fundam Clin Pharmacol.
1997;11138- 142Link to Article
CM β-Blocker therapy for heart failure. JAMA.
2000;2831335- 1337Link to Article
MERIT-HF Group, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet.
1999;3532001- 2007Link to Article
A The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. Clin Cardiol. 1999;22
et al. MERIT-HF Study Group, Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA.
2000;2831295- 1302Link to Article
et al. PRECISE Study Group, Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation.
1996;942793- 2799Link to Article
et al. MOCHA Investigators, Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation.
1996;942807- 2816Link to Article
et al. US Carvedilol Heart Failure Study Group, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med.
1996;3341349- 1355Link to Article
The BEST Steering Committee, Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol.
1995;751220- 1223Link to Article
MThe BEST Steering Committee, BEST (Beta-Blocker Evaluation Survival Trial). Paper presented at: 1999 Scientific Sessions of the American Heart Association November 7-10, 1999 Atlanta, Ga
et al. Effect of carvedilol on LV function and mortality in diabetic versus non–diabetic patients with ischemic or nonischemic dilated cardiomyopathy [abstract]. Circulation.
1996;94I- 644Link to Article
et al. Randomized Aldactone Evaluation Study Investigators, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med.
1999;341709- 717Link to Article
et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol.
1988;61371- 375Link to Article
MKPROVED Investigative Group, Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol.
1993;22955- 962Link to Article
The Digitalis Investigators Group, The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med.
1997;336525- 533Link to Article
et al. ELITE Study Investigators, Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet.
1997;349747- 752Link to Article
JNVasodilator Heart Failure Trial (V-HeFT) Study Group, Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin-converting enzyme inhibitor therapy in patients with heart failure. Circulation.
1999;992658- 2664Link to Article
PB Rationale, background, and design of the Randomized Angiotensin Receptor Antagonist–Angiotensin-Converting Enzyme Inhibitor Study (RAAS). Am J Cardiol.
1996;781129- 1131Link to Article
P Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD pilot study) [abstract]. Eur Heart J. 1998;19188A
B ELITE II (Evaluation of Losartan in the Elderly) Study: the Losartan Heart Failure Survival Study. Paper presented at: 1999 Scientific Sessions of the American Heart Association November 7-10, 1999 Atlanta, Ga
et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med.
1986;3141547- 1552Link to Article
et al. Prospective Randomized Amlodipine Survival Evaluation Study Group, Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med.
1996;3351107- 1114Link to Article
S Long-term morbidity and mortality trials with amlodipine. J Cardiovasc Pharmacol.
S1- S6Link to Article
M PRAISE-2: Prospective Randomized Amlodipine Survival Evaluation. Paper presented at: 49th Scientific Sessions of the American College of Cardiology March 12-15, 2000 Anaheim, Calif
et al. Vasodilator-Heart Failure Trial (V-HeFT) Study Group, Effect of calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation.
1997;96856- 863Link to Article
et al. Vesnarinone Trial, A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med.
1999;3391810- 1816Link to Article
M Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther.
1998;63682- 685Link to Article
et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstract]. Circulation. 1986;74II- 138
et al. Vesnarinone Study Group, Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med.
1993;329149- 155Link to Article
RGrupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA), Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet.
1994;344493- 498Link to Article
et al. Survivial Trial of Antiarrhythmic Therapy in Congestive Heart Failure, Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med.
1995;33377- 82Link to Article
et al. SWORD Investigators, Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet.
1996;3487- 12Link to Article
et al. Danish Investigators of Arrhythmia and Mortality on Dofetilide Study Group, Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med.
1999;341857- 865Link to Article
SZ Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol.
1998;31745- 748Link to Article
RI The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol.
1981;47525- 531Link to Article
MA Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol.
1998;31749- 753Link to Article
Cardiosource, The Warfarin Aspirin Study in Heart Failure (WASH Trial). Available at: http://www.cardiosource.com
. Accessed May 1, 2000.
JL Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology.
2000;54288- 294Link to Article
JB Heart failure therapy: not as complicated as it looks [editorial]. Clin Cardiol.
1999;22333Link to Article